Nutra Pharma
Public biotechnology company focused on acquisition, licensing, development and commercialization of pharmaceutical and OTC homeopathic products. R&D emphasizes chemically modified receptor-binding peptides derived from snake venoms for treatment of viral, neurological and autoimmune diseases. Maintains a patent portfolio, engages with regulators (including FDA), and publishes/maintains preclinical research supporting its drug candidates.
Industries
Nr. of Employees
small (1-50)
Nutra Pharma
Coral Springs, Florida, United States, North America
Products
RPI-78M (modified alpha-cobratoxin therapeutic candidate)
Proprietary chemically modified alpha-cobratoxin-derived therapeutic candidate under development for multiple sclerosis and other autoimmune/neurological disorders; reported oral administration capability and FDA orphan designation for pediatric MS.
RPI-MN (modified cobra-venom-derived antiviral candidate)
Therapeutic candidate derived from modified cobra venom peptides intended to inhibit viral entry for treatment of viral diseases such as HIV and herpes.
OTC homeopathic pain formulations for humans and companion animals
Topical gels, roll-ons and oral sprays formulated as homeopathic pain relievers and anti-inflammatories for human use and a formulation for dogs and cats marketed for chronic pain relief.
RPI-78M (modified alpha-cobratoxin therapeutic candidate)
Proprietary chemically modified alpha-cobratoxin-derived therapeutic candidate under development for multiple sclerosis and other autoimmune/neurological disorders; reported oral administration capability and FDA orphan designation for pediatric MS.
RPI-MN (modified cobra-venom-derived antiviral candidate)
Therapeutic candidate derived from modified cobra venom peptides intended to inhibit viral entry for treatment of viral diseases such as HIV and herpes.
OTC homeopathic pain formulations for humans and companion animals
Topical gels, roll-ons and oral sprays formulated as homeopathic pain relievers and anti-inflammatories for human use and a formulation for dogs and cats marketed for chronic pain relief.
Services
Licensing and commercialization of pharmaceutical products
Licensing-in and commercial distribution support for pharmaceutical and OTC homeopathic products.
Licensing and commercialization of pharmaceutical products
Licensing-in and commercial distribution support for pharmaceutical and OTC homeopathic products.
Expertise Areas
- Venom-derived peptide drug discovery
- Preclinical in vivo research
- Clinical product development and regulatory strategy
- Patent portfolio and intellectual property management
Key Technologies
- Chemical modification of peptides/neurotoxins
- Therapeutic peptide/protein development
- Oral delivery formulation for biologics
- Preclinical animal disease models